In patients with prostate cancer, BRCA2 and ATM defects, TP53 mutations, and AR gene structural rearrangements were strongly associated with poor clinical outcome of patients treated with androgen receptor‐directed therapies.21 Here, TP53 is linked to Familial prostate cancer.